Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee

NCT00120900 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1340

Last updated 2017-01-19

No results posted yet for this study

Summary

This study was designed to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

GW406381

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Denmark
  • Netherlands
  • Norway
  • South Korea
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120900 on ClinicalTrials.gov